Plus Therapeutics provided a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC, on June 26, 2025. The update included plans for the U.S. commercial rollout of its novel diagnostic platform.
The U.S. commercial rollout of the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) test is set to begin in the second half of 2025, starting in Texas. The total addressable market for CNSide TCE is estimated to be $6 billion in the U.S.
The CNSide platform has a strong track record, with over 11,000 tests performed at over 200 U.S. cancer institutions since 2020. It has demonstrated high sensitivity (92%) and specificity (95%), influencing treatment decisions in 90% of cases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.